ALOS4 is a proprietary nonapeptide that was identified (Pinhasov, Ashur-Fabian) as a ligand of integrin αVβ3 in a phage display experiment. Preclinical studies have demonstrated that ALOS4 was able to inhibit the differentiation of macrophages, and to reduce inflammation in both in vitro and in vivo models.
Moreover, in various mouse models for melanoma, it was shown that ALOS4 has an anti-cancer effect on early-stage tumors and is generally safe. The current aim of the project is to explore the underling mechanism of action and to further develop ALOS4 as an anti-inflammatory drug.
Current team members: Noa Davis, Tzachi Morad.
Former team members: Albert Pinhasov, Elimelech Nesher, Osnat Ashur-Fabian, Boris Redko, Michael Kirby, Maria Becker, Bar Shoval, Shiri Yacobovitch–Wissotzky, Lena Tuchinski.